Findings

What do systematic reviews say?

31 questions · 31 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 14 · 45.2%Low 9 · 29%Moderate 8 · 25.8%High 0 · 0%

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

QUETIAPINE vs Typical antipsychotics

Leaving the study early · patients with schizophrenia

Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.91 [0.81, 1.01]
23 studies · 3576 participants
Moderate

COMPARISON 1. ARIPIPRAZOLE vs QUETIAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 2. ARIPIPRAZOLE changes leaving the study early compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.8 [0.22, 2.87]
2 studies · 168 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs RISPERIDONE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 3. ARIPIPRAZOLE changes leaving the study early compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.02 [0.79, 1.32]
12 studies · 1239 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs ZIPRASIDONE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes leaving the study early compared with ZIPRASIDONE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.94 [0.66, 1.34]
2 studies · 316 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs OLANZAPINE

Leaving the study early · patients with schizophrenia

COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.15 [1.05, 1.25]
9 studies · 2331 participants
Low

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.46 [0.11, 1.9]
1 study · 93 participants
Very low

Pericyazine vs Typical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.46 [0.11, 1.9]
2 studies · 71 participants
Very low

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.07, 14.85]
1 study · 38 participants
Moderate

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.74]
1 study · 42 participants
Low

Levomepromazine vs Typical antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.4 [0.09, 1.81]
1 study · 38 participants
Moderate

Levomepromazine vs Typical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1.11 [0.45, 2.74]
1 study · 41 participants
Low

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.67, 1.49]
2 studies · 106 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3.05 [1.12, 8.31]
1 study · 62 participants
Low

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 2 [0.2, 19.62]
1 study · 28 participants
Very low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.6 [0.45, 0.81]
1 study · 749 participants
Low

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.07, 14.85]
1 study · 38 participants
Moderate

COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.41 [0.46, 4.29]
3 studies · 240 participants
Very low

Levomepromazine vs Typical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 4.77 [0.24, 93.67]
1 study · 41 participants
Low